37748-11-1

Upstream product

• 37748-10-0 methyl (3-formylphenoxy)acetate 
• 51264-68-7 ethyl 2-(3-formylphenoxy)acetate 
• 620-24-6 3-Hydroxybenzyl alcohol 
• 96-32-2 bromoacetic acid methyl ester 
• 100-83-4 meta-hydroxybenzaldehyde 

Downstream Products

• 37748-08-6 methyl 3-(chloromethyl)-phenoxyacetate 
• 136645-26-6 methyl <3-(bromomethyl)phenoxy>acetate 
• 98892-38-7 {3-[(1S,2R,3R,4R)-3-((R)-3-Hydroxy-oct-1-ynyl)-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl]-phenoxy}-acetic acid methyl ester 
• 98892-36-5 {3-[(1R,2S,3R,4S)-3-((R)-3-Hydroxy-oct-1-ynyl)-bicyclo[2.2.1]hept-2-ylmethyl]-phenoxy}-acetic acid methyl ester 
• 98892-36-5 {3-[(1S,2R,3S,4R)-3-((R)-3-Hydroxy-oct-1-ynyl)-bicyclo[2.2.1]hept-2-ylmethyl]-phenoxy}-acetic acid methyl ester 
• 98892-41-2 {3-[(1S,2R,3R,4R)-3-((R)-3-Hydroxy-oct-1-ynyl)-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl]-phenoxy}-acetic acid 
• 98892-41-2 {3-[(1R,2S,3S,4S)-3-((R)-3-Hydroxy-oct-1-ynyl)-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl]-phenoxy}-acetic acid 
• 98892-37-6 {3-[(1S,2S,3R,4R)-3-((R)-3-Hydroxy-oct-1-ynyl)-bicyclo[2.2.1]hept-5-en-2-ylmethyl]-phenoxy}-acetic acid methyl ester 
• 98892-37-6 {3-[(1R,2R,3S,4S)-3-((R)-3-Hydroxy-oct-1-ynyl)-bicyclo[2.2.1]hept-5-en-2-ylmethyl]-phenoxy}-acetic acid methyl ester 
• 98892-39-8 {3-[(1R,2S,3R,4S)-3-((R)-3-Hydroxy-oct-1-ynyl)-bicyclo[2.2.1]hept-2-ylmethyl]-phenoxy}-acetic acid 
• 98892-39-8 {3-[(1S,2R,3S,4R)-3-((R)-3-Hydroxy-oct-1-ynyl)-bicyclo[2.2.1]hept-2-ylmethyl]-phenoxy}-acetic acid 
• 98892-40-1 {3-[(1S,2S,3R,4R)-3-((R)-3-Hydroxy-oct-1-ynyl)-bicyclo[2.2.1]hept-5-en-2-ylmethyl]-phenoxy}-acetic acid 
• 98892-40-1 {3-[(1R,2R,3S,4S)-3-((R)-3-Hydroxy-oct-1-ynyl)-bicyclo[2.2.1]hept-5-en-2-ylmethyl]-phenoxy}-acetic acid 

Relevant academic research and scientific papers

AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS

Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.

PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Provided herein are compounds of formula (I) useful for the treatment of PPAR-delta related diseases (e.g. mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases).

12-ARYL PROSTAGLANDIN ANALOGS

Compounds comprising the formula (I) are disclosed, wherein Y, A, X, R, D, and n are as described. A compound comprising a prostaglandin EP2 selective agonist wherein the ω-chain comprises a substituted phenyl, wherein at least one substituent

THERAPEUTIC SUBSTITUTED PIPERIDONE COMPOUNDS

Compounds comprising (Formula 1) or a pharmaceutically acceptable salt or a prodrug thereof are disclosed herein. Details are provided herein. Compositions, methods, and medicaments related thereto are also disclosed. The compounds disclosed are useful fo

Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators

This invention relates to compounds which are generally IP receptor modulators, particularly IP receptor agonists, and which are represented by Formula I: wherein R1, R2, R3, R4, R5, A, and B are as defined in the specification, and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.

3-AMIDINOANILINE DERIVATIVES, ACTIVATED BLOOD COAGULATION FACTOR X INHIBITORS, AND INTERMEDIATES FOR PRODUCING BOTH

The present invention relates to a 3-amidinoaniline derivative represented by the general formula: wherein R represents a hydrogen atom, a lower alkyl group, a lower alkenyl group etc.; R1 represents a hydrogen atom, a hydroxy group, a lower alkyl group etc.; Y represents a single bond or an oxygen atom; and R2 represents a lower alkyl group or a group represented by the general formula: wherein n represents 1 or 2; and T represents a hydrogen atom or a group represented by the general formula:-C(=NH)-W wherein W represents a lower alkyl group; or a pharmaceutically acceptable salt thereof, which has a potent and selective activated blood coagulation factor X inhibitory activity, and an intermediate for producing both.

Organopalladium Approaches to Prostaglandins. 6. Synthesis of Interphenylene Prostaglandin Endoperoxide Analogs Via Benzylpalladation of Bicyclic Alkenes.

The reactions of norbornene, norbornadiene and 7-oxanorbornene with methyl 3-(chloromethyl)phenoxyacetate (4), optically pure (S)-1-octyn-3-ol (5), and 8percent Pd(PPh3)4 afford in one step satisfactory yields of the corresponding esters 6, 7 and 8 respectively, readily saponified to the first interphenylene prostaglandin endoperoxide analogs 10, 11 and 12 respectively.

PGE1 -oxa phenylene compounds

This invention is a group of PGE1 -type oxa-phenylene compounds, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

PGEo oxa-phenylene compounds

This invention is a group of 13,14-dihydro-PGE1 -type (also referred to as PGEo -type) oxa-phenylene compounds, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

PGA1 -oxa-phenylene compounds

This invention is a group of PGA1 -type oxa-phenylene compounds, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, treatment of asthma, and management of renal dysfuction.